Heart Failure

Cardiovascular Clinical Consult

Adult Immunization

Hepatic Disease 

Behcet’s Disease

Rare Disorders

Pediatric Immunization

Implementing The Topcon Ocular Telehealth Platform

Weight Management

Screening

Monkeypox

Guidelines

Men's Health

Panic Disorder  

Anxiety

Eating Disorders

Depression

Substance-related Disorders

ADHD

Psychiatry 

Seasonal Allergies

Allergy

Nutrition 

Pregnancy and Birth

Women's Health

Atrial Fibrillation

Cholesterol Disorders

Cardiovascular Disease

Hypertension

Cardiology

Substance Use

Child/Adolescent

Pediatrics

Kidney Disease

Genetics

Medical Cannabis

Complimentary & Alternative Medicine

Skin Diseases

Dermatology

Thyroid Disorders 

Diabetes

Diabetes Type 2

Insulin

Endocrinology 

Oral Medicine 

Otorhinolaryngologic Diseases

Fibromyalgia

Pain

Irritable Bowel Syndrome 

Inflammatory Bowel Disease

Gastrointestinal Disorders

Geriatrics

Coronavirus

Hepatitis C

Cold, Cough, and Flu

Bacterial Conjunctivitis

Immunization

Influenza

HIV AIDS

Sexually Transmitted Diseases

Infection

Osteoporosis

Imaging 

Musculoskeletal Disorders  

Obesity

Rheumatoid Arthritis

Arthritis

Gout

Rheumatology

Technology

Colorectal Cancer

Kidney Cancer

Lung Cancer

Melanoma

Skin cancer

Prostate Cancer

Breast Cancer

Cervical Cancer

Cancer

Nephrology

Anemia

Dementia

Epilepsy

Cerebrovascular Diseases

Headache and Migraine

Parkinson Disease

Alzheimer disease

Stroke

Mental Health

Headache

Migraine

Nervous System Diseases

Sleep Disorders

Neurology

Asthma

Cystic Fibrosis

COPD

Pneumonia

Respiratory Diseases

Pulmonology

News

All News

Office Procedures

Practice Management

Media

Around the Practice

Between the Lines

ConsultantLive

Expert Interviews

Frontline Insights

Institutional Insights

Medical World News

Podcasts

Primary View

Provider Toolkits

Readout360

Conferences

Conference Coverage

Conference Listing

Resources

Image IQ

Interactive Posters

Polls

Publications

Quizzes

Subscribe

CE/CME

Advertise

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Information

Patient Care Online

Facebook

LinkedIn

Clinical Focus

Allergy & Immunology

Endocrinology

Gastroenterology

Infectious Disease

Men’s Health

Pain Management

Psychiatry

Women’s Health

Business Focus

Billing and Collections

Career Planning

Coding and Documentation

Concierge Medicine

Cybersecurity

EHRs

Investing

Patient Relations

Personal Finance

Remote Patient Monitoring

Staffing

Telehealth

Value-based Care

Spotlight

Unmet Needs in Managing MDD

Interpreting Thyroid Function Tests

Using Thyroid Lab Tests

Testing & Screening to Optimize Men's Health

1rem

Clinical Topics

Topics

Articles

Dapagliflozin is renoprotective and cardioprotective in chronic kidney disease patients, suggests a secondary analysis of the DAPA-CKD trial presented at Kidney Week 2020. 

Kidney Week: Dapagliflozin Renoprotective, Cardioprotective in CKD Patients

 to subscribe on your favorite streaming service.

The Primary Viewpoints podcast features informative conversations with health care experts, opinion leaders, and practicing physicians, about what impacts primary care medicine today.

In episode 17, Dr Hiddo Heerspink, joins us to discuss findings he recently presented at the American Diabetes Association 2022 Scientific Sessions from a 

 he led of the SURPASS-4 clinical trial of tirzepatide that looked for the first time at the effects of the novel GLP-1 receptor agonist on kidney function in patients with type 2 diabetes.

Hiddo Heerspink, PhD, PharmD, is professor of clinical trials and personalized medicine and a clinical pharmacologist/trialist in the department of clinical pharmacy and pharmacology at the University Medical Center Groningen in Groningen, Netherlands; he is also Codirector of the Better Treatments Program at the George Institute for Global Health in Newtown, Australia.

 to subscribe to the Primary Viewpoints podcast. Be sure to leave a rating and review for the show. Thanks for listening!

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD. 

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 11 to 3 against recommending the SGLT1/SLGT2 inhibitor to treat adults with T1D and CKD. 

Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD

In a post hoc analysis of the SCORED trial, investigators observed positive renal protection with sotagliflozin across a spectrum of baseline kidney function and glycemic control.

New Data on Renal Protective Benefits of Sotagliflozin Will be Presented at Kidney Week 2024

Lexicon's sotagliflozin is on the October 31 docket for discussion by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee; PDUFA goal date remains set for December 20.   

Sotagliflozin in Patients with Type 1 Diabetes and CKD to be Discussed at October FDA AdComm Meeting 

The sGC activator represents a novel approach to modulating the nitric oxide-soluble sGC-cyclic guanosine monophosphate pathway. 

Bayer: Phase 2 Trial of Investigational Soluble Guanylate Cyclase Activator for Chronic Kidney Disease Begins

ADA 2024. Semaglutide benefits were observed for adults with type 2 diabetes and chronic kidney disease whether or not they used SGLT-2 inhibitors, according to an analysis of FLOW trial data.

FLOW Trial: Semaglutide Lowers Risk for Major Kidney Disease, CV Events and Death Regardless of SGLT-2i Use

"Drugs don't belong to specialties. They ultimately belong to the patients who take them," said renowned cardiologist and professor of medicine Mikhail Kosiborod, MD, during an interview with Patient Care Online. 

Kosiborod and Neil Skolnik, MD, professor of family and community medicine and well-known primary care educator, spoke together with Patient Care about how and where the sodium glucose contransporter-2 (SGLT-2) inhibitor class of medications are being prescribed, and whether their full range of potency against cardiometabolic disease is fully appreciated yet, across specialties and in primary care. 

What emerged in this first of a 3-part interview between a primary care physician and a cardiology specialist is that SGLT-2 inhibitors are not your grandparents' diabetes drugs and that traditional compartmentalization of drugs, diseases, and patient types serves neither patient or clinician. 

For the second part of this interview, please see: 

Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik

is Professor of Medicine, University of Missouri Kansas City, Vice President, Research, Saint Luke’s Health System, Executive Director, Cardiometabolic Center Alliance, Director, Cardiometabolic Research and Co-director, Haverty Cardiometabolic Center of Excellence, Saint Luke’s Mid America Heart Institute, Kansas City, MO. 

 is Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA.

Videos

Mikhail Kosiborod, MD, a cardiologist and Neil Skolnik, MD, a primary care physician, agree that whoever is seeing the patient should prescribe the drug that is needed. 

SGLT-2 Inhibitors Belong to Patients, Not a Specialty or Primary Care: Experts Discuss 

In an interview with University of Glasgow cardiologist Professor John McMurray about results of the recent DAPA-CKD trial he told Patient Care he doesn't find the word "revolutionary" at all an exaggeration to describe the SGLT2 inhibitor class of drugs. 

McMurray was lead investigator for DAPA-CKD. The primary endpoint, a composite of decline in eGFR ≥50%, end-stage kidney disease, death from renal causes, or cardiovascular death for dapagliflozin vs placebo, was 9.2% vs. 14.5%. The benefit of dapagliflozin on the primary endpoint was consistent in patients with and without type 2 DM. The trial was stopped early due to benefit. 

Patients with chronic kidney disease have had no treatment options to slow the certain progression to renal failure. Enter SGLT2 inhibitors. A key clinical trial investigator explains. 

SGLT2 Inhibitors Enter Vast Treatment Void for High-risk CKD Patients 

Kidney Disease

Latest News

More News